Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know

被引：2
作者：
Opitz, Isabelle [1 ]
Bueno, Raphael [2 ]
Lim, Eric [3 ,4 ]
Pass, Harvey [5 ]
Pastorino, Ugo [6 ]
Boeri, Mattia [7 ]
Rocco, Gaetano [8 ]
机构：
[1] Univ Zurich Hosp, Div Thorac Surg, CH-8091 Zurich, Switzerland
[2] Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA
[3] Univ London Imperial Coll Sci Technol & Med, London, England
[4] Royal Brompton Hosp, Acad Div Thorac Surg, London SW3 6LY, England
[5] NYU, Langone Med Ctr, Dept Cardiothorac Surg, New York, NY USA
[6] Ist Nazl Tumori, Div Thorac Surg, I-20133 Milan, Italy
[7] Ist Nazl Tumori, Tumor Genom Unit, I-20133 Milan, Italy
[8] Fdn G Pascale, IRCCS, Inst Nazl Tumori, Dept Thorac Surg & Oncol, Naples, Italy
来源：
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY | 2014年 / 46卷 / 04期
关键词：
Malignant pleural mesothelioma; Lung cancer; Biomarker; microRNAs; Genomic sequencing; SERUM OSTEOPONTIN LEVELS; PLASMA OSTEOPONTIN; DIAGNOSIS; MICRORNAS; DNA; EXPRESSION; BIOMARKERS; SURVIVAL; QUANTIFICATION; VALIDATION;
D O I：
10.1093/ejcts/ezu048
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Today, molecular-profile-directed therapy is a guiding principle of modern thoracic oncology. The knowledge of new biomolecular technology applied to the diagnosis, prognosis, and treatment of lung cancer and mesothelioma should be part of the 21st century thoracic surgeons' professional competence. The European Society of Thoracic Surgeons (ESTS) Biology Club aims at providing a comprehensive insight into the basic biology of the diseases we are treating. During the 2013 ESTS Annual Meeting, different experts of the field presented the current knowledge about diagnostic and prognostic biomarkers in malignant pleural mesothelioma including new perspectives as well as the role and potential application of microRNA and genomic sequencing for lung cancer, which are summarized in the present article.
引用
收藏
页码：602 / 606
页数：5
相关论文
共 51 条
  • [1] Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
    Aberle, Denise R.
    Adams, Amanda M.
    Berg, Christine D.
    Black, William C.
    Clapp, Jonathan D.
    Fagerstrom, Richard M.
    Gareen, Ilana F.
    Gatsonis, Constantine
    Marcus, Pamela M.
    Sicks, JoRean D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) : 395 - 409
  • [2] SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis
    Aguirre-Gamboa, Raul
    Gomez-Rueda, Hugo
    Martinez-Ledesma, Emmanuel
    Martinez-Torteya, Antonio
    Chacolla-Huaringa, Rafael
    Rodriguez-Barrientos, Alberto
    Tamez-Pena, Jose G.
    Trevino, Victor
    [J]. PLOS ONE, 2013, 8 (09):
  • [3] New Dual Monoclonal ELISA for Measuring Plasma Osteopontin as a Biomarker Associated with Survival in Prostate Cancer: Clinical Validation and Comparison of Multiple ELISAs
    Anborgh, Pieter H.
    Wilson, Sylvia M.
    Tuck, Alan B.
    Winquist, Eric
    Schmidt, Nancy
    Hart, Russell
    Kon, Shigeyuki
    Maeda, Masahiro
    Uede, Toshimitsu
    Stitt, Larry W.
    Chambers, Ann F.
    [J]. CLINICAL CHEMISTRY, 2009, 55 (05) : 895 - 903
  • [4] Comparisons of microRNA Patterns in Plasma before and after Tumor Removal Reveal New Biomarkers of Lung Squamous Cell Carcinoma
    Aushev, Vasily N.
    Zborovskaya, Irina B.
    Laktionov, Konstantin K.
    Girard, Nicolas
    Cros, Marie-Pierre
    Herceg, Zdenko
    Krutovskikh, Vladimir
    [J]. PLOS ONE, 2013, 8 (10):
  • [5] Benefits and Harms of CT Screening for Lung Cancer A Systematic Review
    Bach, Peter B.
    Mirkin, Joshua N.
    Oliver, Thomas K.
    Azzoli, Christopher G.
    Berry, Donald A.
    Brawley, Otis W.
    Byers, Tim
    Colditz, Graham A.
    Gould, Michael K.
    Jett, James R.
    Sabichi, Anita L.
    Smith-Bindman, Rebecca
    Wood, Douglas E.
    Qaseem, Amir
    Detterbeck, Frank C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (22): : 2418 - 2429
  • [6] MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004)
    Bartel, David P.
    [J]. CELL, 2007, 131 (04) : 11 - 29
  • [7] MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer
    Boeri, Mattia
    Verri, Carla
    Conte, Davide
    Roz, Luca
    Modena, Piergiorgio
    Facchinetti, Federica
    Calabro, Elisa
    Croce, Carlo M.
    Pastorino, Ugo
    Sozzi, Gabriella
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (09) : 3713 - 3718
  • [8] Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases
    Chen, Xi
    Ba, Yi
    Ma, Lijia
    Cai, Xing
    Yin, Yuan
    Wang, Kehui
    Guo, Jigang
    Zhang, Yujing
    Chen, Jiangning
    Guo, Xing
    Li, Qibin
    Li, Xiaoying
    Wang, Wenjing
    Zhang, Yan
    Wang, Jin
    Jiang, Xueyuan
    Xiang, Yang
    Xu, Chen
    Zheng, Pingping
    Zhang, Juanbin
    Li, Ruiqiang
    Zhang, Hongjie
    Shang, Xiaobin
    Gong, Ting
    Ning, Guang
    Wang, Jun
    Zen, Ke
    Zhang, Junfeng
    Zhang, Chen-Yu
    [J]. CELL RESEARCH, 2008, 18 (10) : 997 - 1006
  • [9] Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma-Which is best?
    Creaney, Jenette
    Yeoman, Deborah
    Musk, Arthur William
    de Klerk, Nicholas
    Skates, Steven J.
    Robinson, Bruce W. S.
    [J]. LUNG CANCER, 2011, 74 (01) : 55 - 60
  • [10] Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma
    Cristaudo, Alfonso
    Bonotti, Alessandra
    Simonini, Silvia
    Vivaldi, Agnese
    Guglielmi, Giovanni
    Ambrosino, Nicolino
    Chella, Antonio
    Lucchi, Marco
    Mussi, Alfredo
    Foddis, Rudy
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (09) : 1587 - 1593
123456